CN Stock MarketDetailed Quotes
300966 Hubei Goto Biopharm
- 18.35
- +0.02+0.11%
Pre-Opening Auction Nov 18 09:30 CST
2.12BMarket Cap-151652P/E (TTM)
0.00High0.00Low0lotVolume0.00Open18.33Pre Close0.00Turnover0.00%Turnover Ratio91.75P/E (Static)115.28MShares25.6852wk High2.51P/B1.38BFloat Cap12.0152wk Low22.00Limit Up75.13MShs Float79.83Historical High14.66Limit Down0.00%Amplitude12.01Historical Low0.02Dividend TTM--Avg Price0lotAsk0.09%Div YieldTTM100Lot Size0lotBid
Hubei Goto Biopharm Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -5.10%365.39M | -12.69%233.82M | 2.35%122.23M | -6.31%566.4M | -13.83%385.04M | -0.20%267.82M | -0.85%119.42M | 2.32%604.57M | 0.20%446.82M | -11.34%268.35M |
| Operating revenue | -5.10%365.39M | -12.69%233.82M | 2.35%122.23M | -6.31%566.4M | -13.83%385.04M | -0.20%267.82M | -0.85%119.42M | 2.32%604.57M | 0.20%446.82M | -11.34%268.35M |
| Other operating revenue | ---- | -1.41%257.99K | ---- | 433.77%897.49K | ---- | 148.91%261.69K | ---- | -93.32%168.14K | ---- | -94.97%105.13K |
| Total operating cost | 9.36%407.87M | -2.75%250.3M | 1.85%122.39M | -4.22%542.21M | -8.30%372.95M | 6.68%257.38M | 10.38%120.17M | 7.15%566.09M | 3.85%406.72M | -7.31%241.26M |
| Operating cost | 5.75%313.41M | -7.16%193.18M | 0.51%95.87M | -5.38%441.28M | -13.20%296.36M | 4.33%208.07M | 8.40%95.38M | 7.21%466.35M | 3.74%341.44M | -10.05%199.44M |
| Operating tax surcharges | -6.56%717.44K | 6.20%578.94K | -33.39%239.98K | 45.48%1M | 60.27%767.81K | 174.12%545.11K | 454.95%360.31K | -55.12%688.31K | -66.24%479.08K | -80.39%198.86K |
| Operating expense | 28.12%4.68M | 1.90%2.47M | -0.39%864.91K | 43.97%7.06M | 41.47%3.65M | 31.50%2.42M | -3.59%868.26K | -10.31%4.91M | -18.54%2.58M | -19.12%1.84M |
| Administration expense | 24.52%43.36M | 27.13%26.68M | 28.38%13.03M | 14.33%44.4M | 27.19%34.82M | 20.15%20.98M | 28.64%10.15M | -11.61%38.83M | -2.99%27.38M | -5.03%17.46M |
| Financial expense | 91.35%13.47M | 64.87%7.12M | 0.59%2.89M | 2.05%10.37M | 32.55%7.04M | -19.20%4.32M | -8.49%2.87M | 92.68%10.16M | 2.26%5.31M | 30.10%5.34M |
| -Interest expense (Financial expense) | 38.52%13.85M | 18.32%8.4M | -12.04%3.36M | -1.43%13.18M | 9.71%10M | 5.68%7.1M | 16.10%3.82M | 158.44%13.37M | 72.95%9.11M | 70.24%6.72M |
| -Interest Income (Financial expense) | 60.88%-763.78K | 63.67%-576.73K | 60.50%-360.14K | -10.89%-2.13M | -14.59%-1.95M | -62.52%-1.59M | -99.30%-911.69K | -61.57%-1.92M | -117.50%-1.7M | -222.70%-976.86K |
| Research and development | 6.33%32.23M | -3.60%20.28M | -9.87%9.51M | -15.61%38.1M | 2.66%30.32M | 23.97%21.04M | 18.60%10.55M | 21.61%45.15M | 20.47%29.53M | 32.89%16.97M |
| Credit Impairment Loss | 302.87%1.48M | -45.91%-1.34M | 235.63%771.67K | -1.57%-4.57M | 71.71%-731.09K | 56.24%-919.63K | 42.09%-568.94K | -685.39%-4.5M | 24.02%-2.58M | -198.65%-2.1M |
| Asset Impairment Loss | 1,567.21%6.73M | 1,005.79%4.16M | ---414.96K | -1,031.90%-7.71M | -117.28%-458.72K | -117.28%-458.72K | ---- | 129.24%827.12K | 720.54%2.66M | 895.71%2.66M |
| Other net revenue | 407.64%15.24M | 1,040.07%6.32M | 1,096.51%2.4M | -1,207.50%-4.66M | 98.73%3M | -70.87%554.35K | -109.91%-240.49K | 205.88%420.7K | 194.90%1.51M | 221.75%1.9M |
| Fair value change income | 100.00%0.05 | 100.00%0.05 | 100.00%0.05 | -199.91%-11.87K | ---11.88K | ---11.88K | -1,658.72%-8.24K | 826.08%11.88K | ---- | ---- |
| Invest income | 668.80%382.37K | 661.70%253.99K | -222.44%-113.76K | 232.79%258.34K | 60.81%-67.22K | 175.80%33.35K | 4,625.13%92.91K | 81.49%-194.55K | 82.92%-171.52K | 95.09%-43.99K |
| -Including: Investment income associates | 286.62%318.05K | 463.56%253.99K | -252.66%-113.76K | 1,580.11%154.88K | ---170.43K | -250.44%-69.86K | 306.32%74.52K | -87.11%9.22K | ---- | --46.44K |
| Asset deal income | -234.78%-226.82K | --27.18K | ---- | 2,788.53%168.3K | 2,515.35%168.3K | --0 | ---- | ---6.26K | ---6.97K | ---11.88K |
| Other revenue | 67.45%6.87M | 68.77%3.23M | 783.43%2.15M | 68.18%7.21M | 153.47%4.1M | 36.02%1.91M | -50.09%243.78K | -6.61%4.29M | -50.07%1.62M | 278.71%1.41M |
| Operating profit | -280.57%-27.24M | -192.40%-10.16M | 326.02%2.24M | -49.80%19.53M | -63.75%15.09M | -62.08%10.99M | -107.06%-988.98K | -37.96%38.9M | -21.05%41.61M | -29.00%28.99M |
| Add:Non operating Income | -18.53%2.83M | -78.39%730.46K | -96.57%149.53K | 103.25%1.92M | 22.45%3.48M | 1,069.48%3.38M | 9,471.78%4.36M | -95.98%944.29K | -63.83%2.84M | -96.08%289.03K |
| Less:Non operating expense | 83,267.48%1.92M | 1,929,384.74%1.91M | 807,042.16%449.09K | 74.87%2.33M | -98.71%2.31K | -98.72%99.23 | 98.50%55.64 | 1,234.37%1.33M | 112.09%178.01K | -96.25%7.75K |
| Total profit | -241.85%-26.33M | -178.91%-11.34M | -42.66%1.94M | -50.37%19.12M | -58.08%18.56M | -50.89%14.37M | -75.97%3.38M | -55.28%38.51M | -26.79%44.28M | -39.01%29.27M |
| Less:Income tax cost | -248.05%-9.8M | -97.38%-4.46M | -247.59%-957.39K | -117.41%-2.17M | -157.51%-2.82M | -186.75%-2.26M | -121.61%-275.44K | -112.42%-999.75K | -26.36%4.9M | -63.59%2.6M |
| Net profit | SL-16.53M | SL-6.89M | -20.76%2.89M | -46.12%21.29M | -45.72%21.38M | -37.64%16.63M | -71.42%3.65M | -49.38%39.51M | -26.84%39.38M | -34.71%26.67M |
| Net profit from continuing operation | -177.32%-16.53M | -141.41%-6.89M | -20.76%2.89M | -46.12%21.29M | -45.72%21.38M | -37.64%16.63M | -71.42%3.65M | -49.38%39.51M | -26.84%39.38M | -34.71%26.67M |
| Less:Minority Profit | -68.04%-2.37M | -110.53%-1.77M | -75.26%-654.22K | -147.96%-1.72M | -162.30%-1.41M | -169.49%-839.93K | -39.29%-373.28K | -161.26%-691.72K | -124.81%-536.73K | -56.91%-311.67K |
| Net profit of parent company owners | -162.16%-14.16M | -129.30%-5.12M | -11.86%3.55M | -42.78%23.01M | -42.92%22.78M | -35.24%17.47M | -69.15%4.02M | -48.67%40.21M | -26.17%39.92M | -34.26%26.98M |
| Earning per share | ||||||||||
| Basic earning per share | -160.00%-0.12 | -126.67%-0.04 | 0.00%0.03 | -42.86%0.2 | -42.86%0.2 | -35.92%0.15 | -72.73%0.03 | -52.81%0.35 | -33.96%0.35 | -45.56%0.2341 |
| Diluted earning per share | -160.00%-0.12 | -126.67%-0.04 | 0.00%0.03 | -42.86%0.2 | -42.86%0.2 | -32.34%0.15 | -72.73%0.03 | -52.81%0.35 | -33.96%0.35 | -48.44%0.2217 |
| Other composite income | ||||||||||
| Total composite income | -177.32%-16.53M | -141.41%-6.89M | -20.76%2.89M | -46.12%21.29M | -45.72%21.38M | -37.64%16.63M | -71.42%3.65M | -49.38%39.51M | -26.84%39.38M | -34.71%26.67M |
| Total composite income of parent company owners | -162.16%-14.16M | -129.30%-5.12M | -11.86%3.55M | -42.78%23.01M | -42.92%22.78M | -35.24%17.47M | -69.15%4.02M | -48.67%40.21M | -26.17%39.92M | -34.26%26.98M |
| Total composite income of minority owners | -68.04%-2.37M | -110.53%-1.77M | -75.26%-654.22K | -147.96%-1.72M | -162.30%-1.41M | -169.49%-839.93K | -39.29%-373.28K | -161.26%-691.72K | -124.81%-536.73K | -56.91%-311.67K |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
% Chg
No Data